Meso Numismatics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 20, 2023 at 10:04 pm
Share
Meso Numismatics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.646828 million compared to USD 0.367697 million a year ago. Net loss was USD 5.86 million compared to USD 1.34 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 0.11 a year ago. Diluted loss per share from continuing operations was USD 0.47 compared to USD 0.11 a year ago. Basic loss per share was USD 0.47 compared to USD 0.11 a year ago. Diluted loss per share was USD 0.47 compared to USD 0.11 a year ago.
For the nine months, sales was USD 1.79 million compared to USD 0.963967 million a year ago. Net loss was USD 9.56 million compared to USD 4.51 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 0.37 a year ago. Diluted loss per share from continuing operations was USD 0.77 compared to USD 0.37 a year ago. Basic loss per share was USD 0.77 compared to USD 0.37 a year ago. Diluted loss per share was USD 0.77 compared to USD 0.37 a year ago.
Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary, Global Stem Cell Group Inc. It distributes stem cells and other regenerative based cell lines and equipment internationally and specializes in education and training physicians in regenerative medicine. It works with doctors and staff to provide products, solutions, equipment, services, and training to help them in the application of stem cell therapies. It is focused on the manufacturing and commercialization of viable cell therapy and immune support-related products. Its professional trademarked association, The International Society for Stem Cell Application (ISCCA), is a global network of medical professionals. Its flagship operation in Istanbul employs targeted combinations of exosomes, allogeneic human mesenchymal cells, and autologous bone marrow and adipose-derived stem cells to treat an array of diseases and debilitating medical conditions.